SELLAS Life Sciences Group, Inc. $SLS is Dagco Inc.’s 10th Largest Position

Dagco Inc. lifted its position in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 19.8% in the second quarter, Holdings Channel reports. The institutional investor owned 1,232,433 shares of the company’s stock after acquiring an additional 203,653 shares during the quarter. SELLAS Life Sciences Group comprises approximately 3.4% of Dagco Inc.’s holdings, making the stock its 10th largest position. Dagco Inc.’s holdings in SELLAS Life Sciences Group were worth $18,191,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in SLS. Vanguard Group Inc. lifted its holdings in SELLAS Life Sciences Group by 2.8% in the third quarter. Vanguard Group Inc. now owns 6,839,905 shares of the company’s stock valued at $11,012,000 after acquiring an additional 185,106 shares during the last quarter. Geode Capital Management LLC increased its stake in SELLAS Life Sciences Group by 35.9% during the fourth quarter. Geode Capital Management LLC now owns 3,077,337 shares of the company’s stock worth $11,604,000 after acquiring an additional 812,953 shares during the last quarter. Marshall Wace LLP raised its position in SELLAS Life Sciences Group by 23,550.0% in the second quarter. Marshall Wace LLP now owns 2,715,489 shares of the company’s stock valued at $5,947,000 after purchasing an additional 2,704,007 shares during the period. State Street Corp raised its position in SELLAS Life Sciences Group by 60.8% in the fourth quarter. State Street Corp now owns 2,188,171 shares of the company’s stock valued at $8,249,000 after purchasing an additional 827,257 shares during the period. Finally, Millennium Management LLC lifted its stake in shares of SELLAS Life Sciences Group by 341.0% in the 4th quarter. Millennium Management LLC now owns 1,387,849 shares of the company’s stock valued at $5,232,000 after purchasing an additional 1,073,147 shares during the last quarter. Hedge funds and other institutional investors own 17.38% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a report on Monday, July 6th. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $10.00.

SELLAS Life Sciences Group Stock Performance

Shares of SLS stock opened at $11.05 on Wednesday. SELLAS Life Sciences Group, Inc. has a fifty-two week low of $1.39 and a fifty-two week high of $15.88. The company has a 50 day moving average price of $11.01 and a 200 day moving average price of $7.24. The stock has a market capitalization of $2.17 billion, a P/E ratio of -48.04 and a beta of 2.48.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.